Establishing a cost recovery system for drugs, Bo, Sierra Leone

Thuray, H; Samai, O; Fofana, P; Sengeh, Paul

doi:10.1016/s0020-7292(97)00159-8

Cited by 7 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two references reported on the Affordable Medicines Facility-malaria (AMFm), which provided subsidies to manufacturers of artemisinin-based combination therapies (ACT) at the global level, and which resulted in price reductions for ACTs to consumers36 and increased availability of ACTs in various countries in Sub-Saharan Africa 3637 Other references reported cost savings from public procurement of drugs (compared to private sector only) in Mali,38 the implementation of an IT system to purchase hospital supplies in India39 and the direct purchase of drugs from commercial suppliers rather than through government channels in Sierra Leone 40…”

Section: Resultsmentioning

confidence: 99%

Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries

Seidman

Atun

2017

BMJ Glob Health

View full text Add to dashboard Cite

IntroductionImproving health systems performance, especially in low-resource settings facing complex disease burdens, can improve population health. Specifically, the efficiency and effectiveness of supply chains and procurement processes for pharmaceuticals, vaccines and other health products has important implications for health system performance. Pharmaceuticals, vaccines and other health products make up a large share of total health expenditure in low-income and middle-income countries (LMICs), and they are critical for delivering health services. Therefore, programmes which achieve cost savings on these expenditures may help improve a health system's efficiency, whereas programmes that increase availability of health products may improve a health system's effectiveness. This systematic review investigates whether changes to supply chains and procurement processes can achieve cost savings and/or improve the availability of drugs in LMICs.MethodsUsing the PRISMA guidelines for systematic reviews, we searched PubMed, Embase, CINAHL and the Health Economic Evaluation Database to identify.ResultsWe identified 1264 articles, of which 38 were included in our study. We found evidence that centralised procurement and tendering can achieve direct cost savings, while supply chain management programmes can reduce drug stock outs and increase drug availability for populations.ConclusionsThis research identifies a broad set of programmes which can improve the ways that health systems purchase and delivery health products. On the basis of this evidence, policymakers and programme managers should examine the root causes of inefficiencies in pharmaceutical supply chain and procurement processes in order to determine how best to improve health systems performance in their specific contexts.

show abstract

Section: Resultsmentioning

confidence: 99%

Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries

Seidman

Atun

2017

BMJ Glob Health

View full text Add to dashboard Cite

show abstract

“…8 The War Powers Act and its successor, the Defense Production Act, allows the President broad authority to redirect domestic production during times of crisis. 9 Moreover, governments of lowand middle-income countries have deployed such models for decades, 10 enabling cashstrapped health systems to provide access to treatments and manufacturers to receive predictable revenues without risking operating losses. But experience with cost-recovery models for drugs is limited in the US.…”

Section: Alternative Pricing Modelsmentioning

confidence: 99%

Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. Pricing in a pandemic is complicated and fraught. The policy puzzle involves balancing lower prices to ensure access to essential medications, vaccines, and tests, and adequate revenue streams to provide manufacturers incentives to make the substantial, risky investments needed to develop products in the first place. We review alternative pricing strategies (cost-recovery models, monetary prizes, advanced market commitments) for coronavirus disease 2019 (COVID-19) drugs, vaccines, and diagnostics. Hybrid pricing strategies are undoubtedly needed in a pandemic, but

show abstract

“…Eight studies (30)(31)(32)(33)(34)(35)(36)(37) used only process indicators as outcome measures, and therefore were unable to draw conclusions about the effect of the interventions on maternal outcomes. These studies, for example, documented that a community loan fund or training programme was implemented, but failed to report any data related to the effect of these initiatives on maternal health.…”

Section: Introductionmentioning

confidence: 99%

Safe motherhood intervention studies in Africa: A review

Luck¹

2009

E Af Med Jrnl

View full text Add to dashboard Cite

Objective: To review the findings of safe motherhood intervention studies conducted in African settings. Data sources: Published literature regarding interventions designed to reduce maternal mortality in African settings. Study selection: Studies conducted in sub-Saharan Africa to assess the effects of interventions designed to reduce maternal mortality. Data extraction: Search of Medline database for the years 1988 to 1998 with additional manual search of references cited in Medline-referenced studies. Data synthesis: Few of the 34 intervention studies identified used a double-blind, randomized controlled trial design (4/34), or outcome measures directly related to maternal mortality or maternal health (7/34). Six of the studies produced reasonably convincing evidence of a positive effect on maternal health outcomes. Of these, three showed that changes in delivery practices brought about improved maternal outcomes, two found that a combined intervention consisting of upgrading of emergency obstetric services and community education increased the number of major obstetric complications treated, and one showed that a range of improvements in hospital equipment and management reduced facility-based maternal mortality ratios. No study sought to reduce maternal mortality associated with unsafe termination of pregnancy. Conclusions: More than a decade after the launching of the Safe Motherhood Initiative, there exists little evidence regarding which interventions will reduce maternal mortality levels in African settings. Intervention studies conducted in Africa have identified several low-tech improvements in emergency obstetric services which improve maternal outcomes and deserve replication and testing in a variety of settings. Further operational research should be conducted to identify and test other promising safe motherhood interventions, in particular interventions designed to reduce the important proportion of maternal mortality associated with unsafe termination of pregnancy. studies, gives an overview of the study designs and outcome measures, and describes the main findings. In a final section, recommendations are made based on the findings of the review. MATERIALS AND METHODS The initial source for the review was the Medline index for the years 1988 to 1999 when this review was conducted. A search using the terms "maternal mortality" and "Africa" yielded more than 600 records; these were culled by omitting non-epidemiologic materials (case studies and editorials). Review of the full text of the most relevant materials revealed additional reports. In all, 188 papers describing epidemiologic studies of maternal mortality in Africa were identified. Of these, just 34 were found to examine the effects of maternal health interventions. The paucity of published reports on maternal intervention studies in Africa is underscored by the fact that 24 (71%) of the 34 identified studies were part of a single Carnegie and MacArthur Foundation funded project, the Prevention of Maternal Mortality Network(3).

show abstract

Establishing a cost recovery system for drugs, Bo, Sierra Leone

Abstract: Cost recovery systems for drugs can help maintain consistent drug supplies at health facilities. Careful pricing is critical. For the system to be sustainable, the mark-up must cover defaulters.

Cited by 7 publications

References 2 publications

Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries

Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries

Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic

Safe motherhood intervention studies in Africa: A review

Contact Info

Product

Resources

About